ASCL1 and small cell lung carcinoma: The BET (bromodomain and extra-terminal) inhibitors have been shown to disrupt the interaction between BRD4 and the ASCL1 enhancer, resulting in the downregulation of ASCL1, and subsequent growth inhibition of SCLC cells37.